PMEF
DSGN icon

Point72 Middle East FZE’s Design Therapeutics DSGN Stock Holding History

Point72 Middle East FZE’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-9,426
Closed -$25K – 392
2023
Q4 		$25K Buy
9,426
+4,501
+91% +$10.3K ﹤0.01% 1348
2023
Q3 		$11.6K Sell
4,925
-4,160
-46% -$19.4K ﹤0.01% 1348
2023
Q2 		$57.2K Sell
9,085
-279
-3% -$1.71K ﹤0.01% 1279
2023
Q1 		$54K Buy
+9,364
New +$70K ﹤0.01% 1258

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Middle East FZE's DSGN Position: Q1 2024 in Review

Point72 Middle East FZE sold out of Design Therapeutics (DSGN) in Q1 2024, closing a stake of 9,426 shares — an estimated $25K sold.

Point72 Middle East FZE first reported a position in DSGN in Q1 2023 and held it in 4 quarters. The position peaked at $57.2K in Q2 2023. 93 funds tracked by Wall St. Rank hold DSGN as of Q1 2024.

  • Point72 Middle East FZE reported no remaining Design Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Point72 Middle East FZE sold 9,426 Design Therapeutics shares in Q1 2024, an estimated $25K.
  • Point72 Middle East FZE first reported a position in Design Therapeutics in Q1 2023 and held it in 4 quarters.
  • Point72 Middle East FZE's Design Therapeutics position peaked at $57.2K in Q2 2023.
  • 93 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2024.

Based on Point72 Middle East FZE's 13F filing for Q1 2024.